FLT3
信号通路图
研究领域
抑制剂选择性比较
FLT3产品
| 目录号 | 产品描述 | 文献引用 | 实验数据 |
|---|---|---|---|
| S1040 |
Sorafenib (BAY 43-9006) tosylateSorafenib (BAY 43-9006) tosylate是Raf-1和B-Raf的多重激酶抑制剂，无细胞试验中IC50分别为6 nM和22 nM。Sorafenib 还可抑制VEGFR-2、VEGFR-3、PDGFR-β、Flt-3和c-KIT，对应的IC50值分别为90 nM、20 nM、57 nM、59 nM和68 nM。Sorafenib Tosylate 可诱导autophagy、apoptosis并激活ferroptosis，并具有抗肿瘤活性。 |
Inhibition of breast cancer cell growth using sorafenib. MCF-7 breast cancer cells were treated with increasing concentrations of sorafenib for 5 days. Cell number was measured using a colorimetric growth assay (crystal violet stain) and expressed relative to DMSO treated control cells. |
|
| S1048 |
Tozasertib (VX-680, MK-0457)Tozasertib (VX-680, MK-0457)是一种pan-Aurora抑制剂，对Aurora A作用最强，无细胞试验中Kiapp为0.6 nM，而对Aurora B/Aurora C的作用较弱，对Aurora A选择性比其他55种激酶高100倍。唯二的例外是 Fms-related tyrosine kinase-3 (FLT-3) 和 BCR-ABL tyrosine kinase，也可被 Tozasertib 抑制，对应的Ki值均为30 nM和30 nM。Tozasertib 可诱导凋亡和自噬。Phase 2。 |
Senescence induction upon PKCι depletion combined with aurora kinase inhibition. ( a) MCF7 cells were transfected as above to deplete PKCι . Two days after transfection, cells were treated for the indicated time period with 400 n M VX-680. Medium with VX-680 was then removed and fresh medium was added. Cells were stained for SA-b -gal activity 5 days after the start of transfection.* indicates a P value <0.05. ( b) MCF7 cells were treated as above. Five days after transfection, cells were fixed and assessed for the presence of gH2AX foci by immunofluorescence microscopy. (c, d) MCF7 cells were treated with dimethyl sulfoxide (DMSO) control or 400 n M VX-680 for the indicated time periods. Total cell lysates were then analyzed by western blotting for levels of p21 and GAPDH (as loading control). A representative blot is shown in panel c. Quantitation of changes in p21 levels (normalized to vehicle-treated controls) is shown in panel d. The data shown are the means ±s.e. of three independent experiments. |
|
| S1460 |
SP600125SP600125 (Nsc75890)是一种广谱JNK抑制剂，作用于JNK1、JNK2和JNK3，无细胞试验中IC50分别为40 nM、40 nM和90 nM，比作用于MKK4选择性高10倍，比作用于MKK3、MKK6、PKB和PKCα选择性高25倍，比作用于ERK2、p38、Chk1、EGFR等选择性高100倍。SP600125也是一种广谱的serine/threonine kinases抑制剂，包括Aurora kinase A、FLT3和TRKA，对应的IC50值为60 nM、90 nM和70 nM。SP600125可抑制自噬而激活细胞凋亡。 |
Loss of DUSP4 function upregulates IL-6 and IL-8 and enhances mammosphere growth. Immunoblot analysis of MDA-231 cells after treatment of 24 hours with 1 umol/L selumetinib (MEKi) or 10 umol/L SP600125 (JNKi). I, MDA-231 mammosphere formation quantitated by GelCount software 7 days after siRNA transfection. Where indicated, selumetinib (MEKi) or SP600125 (JNK1) or the combination was added to the mammosphere cultures.
|
|
| S1111 |
Foretinib (GSK1363089)Foretinib (GSK1363089, EXEL-2880, XL-880, GSK089) 是一种ATP竞争性的HGFR和VEGFR抑制剂，对Met (c-Met)和KDR作用最强，在无细胞试验中IC50分别为0.4 nM和0.9 nM。对Ron， Flt-1/3/4， Kit (c-Kit)， PDGFRα/β和Tie-2作用效果稍弱，对FGFR1和EGFR几乎没有抑制活性。Phase 2。 |
c-MET/RON inhibitors restore sensitivity to lapatinib in SK-BR-3-LR cells. Cell growth was determined using the sulforhodamine B assay. The concentration used was 0.1 uM for crizotinib, MGCD-265, XL880, sunitinib, dasatinib, and TAE-684I. The phosphorylation of HER2, AKT and ERK1/2 was determined by Western blotting.
|
|
| S2194 |
R406R406 是一种有效的 Syk 抑制剂，无细胞试验中IC50为41 nM，对Syk抑制作用强，但是不抑制Lyn，对Flt3的作用比对Syk低5倍。R406 可诱导凋亡。Phase 1。 |
Platelets (3 x 108/mL) were preincubated with Y27632 (10 uM), R406 (1 uM), or a combination of Y27632 and R406 for 20 minutes followed by stimulation with oxLDL (50 ug/mL) for 15 seconds and lysis. Samples were then separated by SDS-PAGE and were immunoblotted for phospho-MLCSer19, followed by reprobing for β-tubulin. (Fi) Representative blots. (Fii) Densitometric analysis of 3 independent experiments. *P < .05. Data are presented as mean ± SEM. Experiments were carried out in the presence of apyrase (2 U/mL), indomethacin (10 uM), and EGTA (1 mM).
|
|
| E0933New |
AristolactamAristolactam (Aristolactam I) is the main active ingredient in the Aristolochia plant species, which have been associated with severe nephrotoxicity. |
||
| S7002New |
ZotiraciclibZotiraciclib (SB1317; TG02)是一种新型小分子CDK/JAK2/FLT3抑制剂，对CDK1、2和9的IC50分别为9、5和3 nM，抑制FLT3的IC50为19 nM，抑制JAK2的IC50为19 nM。 |
||
| S9892New |
HM43239HM43239 是一种新型强效小分子 FLT3 抑制剂，不仅选择性抑制 FLT3 野生型、ITD 突变体或 TKD 突变，还选择性抑制 FLT3 ITD/TKD 双突变。 HM43239 对 FLT3 WT、FLT3 ITD 和 FLT3 D835Y 激酶的 IC50 分别为 1.1 nM、1.8 nM 和 1.0 nM。 |
||
| S9779New |
Emavusertib (CA-4948)Emavusertib (CA-4948) 是一种有效的、口服生物可利用的 interleukin-1 receptor-associated kinase 4/FMS-like Tyrosine Kinase 3 (IRAK4/FLT3) 的抑制剂，具有抗肿瘤活性。 |
||
| S1526 |
Quizartinib (AC220)Quizartinib (AC220)是一种二代FLT3抑制剂，作用于Flt3(ITD/WT)，在MV4-11和 RS4;11细胞中IC50分别为1.1 nM/4.2 nM，作用于Flt3比作用于KIT，PDGFRA，PDGFRB，RET，和CSF-1R选择性高10倍。Quizartinib (AC220)可诱导肿瘤细胞的凋亡。Phase 3。 |
Cotreatment with JQ1 and AC220 synergistically induces apoptosis of FLT3-ITD–expressing AML cells. MV4-11 cells were treated with the indicated concentrations of AC220 and/or JQ1 for 24 hours. At the end of treatment, immunoblot analyses were conducted as indicated. The numbers beneath the blots represent densitometry analysis conducted on representative blots.
|
|
| S1018 |
Dovitinib (TKI-258)Dovitinib (TKI-258, CHIR-258)是一种多靶点的RTK抑制剂，在无细胞试验中对III型(FLT3/c-Kit)作用最强，IC50为1 nM/2 nM，同时也作用于IV类(FGFR1/3)和V类(VEGFR1-4) RTKs，IC50为8-13 nM，但对InsR，EGFR，c-Met，EphA2，Tie2，IGF-1R和HER2作用较弱。Phase 4。 |
Orthotopic xenografts of HNSCC cell lines (A) SCC-1 and (B) OSC-19 were treated with dovitinib (20 mg/kg/day). In addition, the OSC-19 xenografts were treated with +/ radiation therapy. Marker, mean for triplicate; bars, SE. Statistical significance by unpaired t-test, p < 0.05. |
|
| S2736 |
Fedratinib (TG101348)Fedratinib (SAR302503, TG101348)是一种选择性JAK2抑制剂，在无细胞试验中IC50为3 nM，作用于JAK2比作用于JAK1和JAK3选择性高35和334倍。Fedratinib也可抑制 FMS-like tyrosine kinase 3 (FLT3) 和 Ret (c-RET)，对应的IC50值分别为15 nM和48 nM。Fedratinib有潜在的抗肿瘤活性。Fedratinib可抑制细胞增殖并促进凋亡。Phase 2。 |
Colony-forming assay results showing that the Jak2 inhibitor TG101348 reduces CFU-GM colonies generated from mutant fetal liver R2 cells. Results from 4 independent control or mutant fetal livers treated with TG101348 or dimethylsulfoxide (DMSO) are shown (mean ?SD). ***P < .001.
|
|
| S1003 |
Linifanib (ABT-869)Linifanib (ABT-869, AL39324, RG3635)是一种新型有效的ATP竞争性VEGFR/PDGFR抑制剂，作用于KDR，CSF-1R，Flt-1/3和PDGFRβ，其IC50分别为4 nM，3 nM，3 nM/4 nM和66 nM，对突变激酶依赖性癌细胞（即FLT3）最有效。Linifanib (ABT-869) 可诱导自噬和凋亡。Phase 3。 |
(B and C) KMCH-1 cells were plated alone (monoculture) or together with PDGF-BB-secreting LX-2 cells (co-culture) in a transwell insert co-culture system (KMCH-1 cells in the bottom wells and LX-2 cells in the inserts; 1:1 ratio) for 2 days. Cells were treated as indicated with vehicle, rhTRAIL (10 ng/ml for 6 h on day 2), rhTRAIL plus imatinib [rhTRAIL:10 ng/ml for 6 h on day 2; Imatinib: 5 μmol/L for 24 h (day2)], or rhTRAIL plus linifanib [rhTRAIL: 10 ng/ml for 6 h on day 2; Linifanib:0.5 μmol/L for 24 h (day2)]. After rhTRAIL treatment for 6 h,KMCH-1 cells were analysed for apoptotic nuclear morphology by DAPI-staining (B) and for DNA fragmentation by transferasemediated dUTP nick end labelling assay (C) with quantification of apoptotic nuclei by fluorescence microscopy. |
|
| S2730 |
Crenolanib (CP-868596)Crenolanib (CP-868596, ARO 002)是一种有效的，选择性PDGFRα/β抑制剂，在CHO细胞中Kd为2.1 nM/3.2 nM，也能有效抑制FLT3，对D842V突变型敏感对V561D突变型不敏感，作用于PDGFR比作用于c-Kit，VEGFR-2，TIE-2，FGFR-2，EGFR，erbB2，和Src的选择性高100倍以上。Crenolanib可辅助诱导线粒体自噬。 |
Western blot analysis using 4G10 and anti-FLT3 antibody after immunoprecipitation with anti-FLT3 antibody and Western blot analysis of phospho-ERK (pERK) and ERK performed on whole cell lysates from HB119 and Molm14 cells. Cells were exposed to 100 nM crenolanib for 60 min.
|
|
| S2198 |
SGI-1776 free baseSGI-1776 free base是一种新型的，ATP竞争性Pim1抑制剂，无细胞试验中IC50为7 nM，比作用于Pim2和Pim3选择性分别高50和10倍，也有效作用于Flt3和haspin。SGI-1776 可诱导凋亡和自噬。Phase 1。 |
VCaP cells were steroid starved overnight then treated with 10nM R1881 and PIM kinase inhibitor SGI-1776 as indicated for 4 hours. Total protein lysates were analyzed by Western blot with antibodies against P-AR S213, AR (total), P-4EBP1 Thr 37/46, and tubulin.
|
|
| S1533 |
R406 (free base)R406 (free base) 是一种有效的Syk抑制剂，无细胞试验中IC50为41 nM，强效抑制Syk而不能抑制Lyn，对Flt3作用效果低5倍。R406 (free base) 可触发凋亡。Phase 1。 |
(C) Z-138 and JEKO-1 cells were simultaneously exposed to sorafenib and R406 at the indicated doses, and cell viability was determined at 48 hours by annexin V/PI staining. Bars represent the mean ± SD of 3 independent experiments. CI value is indicated for each combination. (D) Primary MCL cells from 7 patients were simultaneously exposed to sorafenib and R406 at the indicated doses for 48 hours, and cell viability was determined as above. Bars represent the mean ± SEM of all the samples analyzed. CI value is indicated for each combination. |
|
| S1244 |
Amuvatinib (MP-470)Amuvatinib (MP-470, HPK 56) 是一种有效的，作用于c-Kit、PDGFα和Flt3的多靶点抑制剂，IC50分别为10 nM、40 nM和81 nM。Amuvatinib 可抑制c-MET和c-RET。Amuvatinib 还具有DNA修复蛋白Rad51抑制剂及抗肿瘤的活性。Phase 2。 |
Inactivation of AXL by MP470 reverses epithelial to mesenchymal transition. Immunoblot analyses of lysates from TGFβ/TNFα- treated MCF10A cells treated with varying amounts of MP470 for 72 hours.
|
|
| S1043 |
Tandutinib (MLN518)Tandutinib (MLN518, CT53518, NSC726292)是一种有效的FLT3拮抗剂，IC50为0.22 μM，同时也抑制PDGFR和c-Kit，对FLT3作用效果比CSF-1R强15到20倍，比FGFR， EGFR和KDR等强100倍以上。Phase 2。 |
|
|
| S2692 |
TG101209TG101209是一种选择性的JAK2抑制剂，无细胞试验中IC50为6 nM，对Flt3和RET (c-RET)作用效果稍弱，IC50分别为25 nM和17 nM，作用于JAK2比作用于JAK3选择性高30倍左右，对JAK2V617F和MPLW515L/K突变型敏感。 |
EGFR-ERCC1 effect on survival. QGP1 cells were transfected with Scrambled, ERCC1, EGFR, or EGFR-ERCC1 siRNA. Following 48 hours of siRNA transfection, Scrambled siRNA and ERCC1 siRNA-transfected cells were treated with 1 umol/L gefitinib or 125 nmol/L NU7026 (DNAPK inhibitor), or both, while EGFR siRNA and EGFR-ERCC1 siRNA-transfected cells were treated with 125 nmol/L of NU7026 1 hour prior 4 Gy IR treatment. Survival of these cells was then assessed 72 hours following IR treatment via MTT assay. The graphs show percentage of survival from 3 independent experiments as compared with untreated control. Bars show SD. Asterisks show statistical significance (*,P < 0.05; **, P < 0.01; ***, P < 0.001; NS, nonsignificant).
|
|
| S2158 |
KW-2449KW-2449是一种多靶点抑制剂，最有效作用于Flt3，IC50为6.6 nM，作用于Flt3， Bcr-Abl和Aurora A适度有效；对PDGFRβ， IGF-1R， EGFR没有抑制效果。Phase 1。 |
Western blot analysis of p-histone and histone. 0-10μM KW2449 was added.
|
|
| S1181 |
ENMD-2076ENMD-2076 选择性地作用于 Aurora A 和 Flt3，IC50分别为14 nM和1.86 nM，作用于Aurora A比作用于Aurora B选择性高25倍，对RET、SRC、NTRK1/TRKA、CSF1R/FMS、VEGFR2/KDR、FGFR和PDGFRα作用效果稍弱。ENMD-2076 可抑制各种人类实体瘤和造血癌细胞系的生长，其IC50值为0.025至0.7μM，可诱导凋亡和G2/M期停滞。Phase 2。 |
Breast cancer cells line MDA-MB-231 were treated with the indicated concentrations of ENMD-2076.
|
|
| S7083 |
Ceritinib (LDK378)Ceritinib (LDK378)是一种有效的ALK抑制剂，在无细胞试验中IC50为0.2 nM。Ceritinib (LDK378)还可抑制IGF-1R、InsR、STK22D和FLT3对应的IC50值分别为8 nM、7 nM、23 nM和60 nM。Phase 3。 |
Quantitation of crystal violet uptake by ORF-expressing cells exposed to crizotinib (CRZ) or ceritinib (CER) normalized to Lac Z. Mean and SE are shown for six (CRZ) or four (CER) independent experiments of three replicates each.
|
|
| S8032 |
PRT062607 (P505-15) HClPRT062607 (P505-15, BIIB057, PRT-2607)是一种新型的，高度选择性Syk抑制剂，无细胞试验中IC50为1 nM，作用于Syk比作用于Fgr，PAK5，Lyn，FAK，Pyk2, FLT3, MLK1 和Zap70选择性高80倍以上。 |
Dectin-1 is involved in activation of NLRP3-inflammasome by Malassezia spp. IL-1b secretion from mature human mono-DCs incubated with Syk-inhibitors (piceatannol, R406 or P505), 1 h prior to exposure to medium, MSU, b-glucan, nigericin or live M. furfur (MOI = 10) was determined after 6 h by ELISA.
|
|
| S7397 |
Sorafenib (BAY 43-9006)Sorafenib (BAY 43-9006, NSC-724772)是Raf-1和B-Raf的多重激酶抑制剂，无细胞试验中IC50分别为6 nM和22 nM。Sorafenib 还可抑制VEGFR-2、VEGFR-3、PDGFR-β、Flt-3和c-KIT，对应的IC50值分别为90 nM、20 nM、57 nM、59 nM和68 nM。Sorafenib 可诱导autophagy、apoptosis并激活ferroptosis，Sorafenib 具有抗肿瘤活性。 |
Involvement of EV linc-VLDLR in tumor cell responses to chemotherapy. Cells were incubated with sorafenib, camptothecin, or doxorubicin. EVs were obtained after 24 hours, and qRT-PCR was performed for linc-VLDLR. The bars represent the mean ?SEM of the increase in cell viability from 3 independent studies. *, P < 0.05.
|
|
| S8057 |
Pacritinib (SB1518)Pacritinib (SB1518)是有效的选择性Janus Kinase 2 (JAK2)和Fms-Like Tyrosine Kinase-3 (FLT3)抑制剂，无细胞试验中IC50分别为23和22 nM。Phase 3。 |
Phosphorylation of the CSF-1R targets indicated was examined by immunoblotting
|
|
| S4001 |
Cabozantinib malate (XL184)Cabozantinib malate (XL184)是Cabozantinib的苹果酸盐，是有效的VEGFR2抑制剂，IC50为0.035 nM，也抑制c-Met， RET (c-RET)， Kit (c-Kit)， Flt-1/3/4， Tie2和AXL，无细胞试验中IC50分别为1.3 nM， 4 nM， 4.6 nM， 12 nM/11.3 nM/6 nM， 14.3 nM和7 nM。Cabozantinib malate (XL184)可诱导细胞凋亡。 |
Effects of AXL inhibitors on induction of pAKT and rescue of pERK following AXL overexpression. R428, 500 nmol/L; XL184, 3 umol/L; XL880, 100 nmol/L; in the presence or absence of 2 umol/L PLX4720. shAXL is a positive control.
|
|
| S8023 |
TCS 359TCS 359是一种有效的FLT3抑制剂，IC50为42 nM。 |
||
| S2018 |
ENMD-2076 L-(+)-Tartaric acidENMD-2076 L-(+)-Tartaric acid 是ENMD-2076的酒石酸，选择性作用于Aurora A和VEGFR(Flt3)，IC50分别为14 nM和1.86 nM，作用于Aurora A比作用于Aurora B选择性高25倍，对VEGFR2/KDR和VEGFR3， FGFR1和FGFR2和PDGFRα作用效果稍弱。Phase 2。 |
Breast cancer cells line MDA-MB-231 were treated with the indicated concentrations of ENMD-2076.
|
|
| S7765 |
Dovitinib (TKI258) LactateDovitinib (TKI258, CHIR258) Lactate是Dovitinib的乳酸盐，Dovitinib是一种多靶点的PTK抑制剂，主要对第III类(FLT3/c-Kit)发挥作用，IC50为1 nM/2 nM，对第IV 类(FGFR1/3)和第V 类(VEGFR1-4) RTKs也有效，IC50为8-13 nM，对InsR，EGFR，c-Met，EphA2，Tie2，IGFR1 和HER2作用较差。Phase 4。 |
(c) Percent survival for the AGS cancer cell line is shown with FGFR2 inhibitors of varying specificity. (d) The KatoIII diffuse gastric cancer cell line was treated with FGFR2 inhibitors of varying specificity. The Y-axis depicts percent survival versus the X-axis with log concentrations. In all panels, error bars represent standard error of the mean. The difference in percent cell survival between KatoIII and AGS cells was statistically significant (P <0.05) at the three highest concentrations of all drugs, except Brivanib which was only significant at the highest concentration. |
|
| S7576 |
UNC2025 HClUNC2025 HCl 是一种有效且口服生物可利用的双重MER/FLT3抑制剂，IC50分别为0.74 nM 和 0.8 nM，选择性比作用于Axl和 Tyro3大约高20倍。 |
||
| S0278 |
SU5614SU5614 (Chloro-SU5416, Chloro-Semaxanib) 是一种小分子 receptor tyrosine kinases (RTK) 的抑制剂，对 VEGFR-2、c-kit 以及野生型和突变型 FLT3 均有抑制作用。SU5614 可减少细胞增殖并诱导凋亡。 |
||
| S8899 |
FF-10101FF-10101是一种新型的不可逆的FLT3抑制剂，对FLT3(WT)和 FLT3(D835Y)的ic50分别为0.20 nM 和 0.16 nM。 |
||
| S7014 |
Merestinib (LY2801653)Merestinib (LY2801653) 是一种2型ATP竞争型的慢抑制剂，抑制Met (c-Met)酪氨酸激酶，Ki值为2 nM。药效的停留时间为0.00132 min(-1)，t1/2为525 min。Merestinib (LY2801653) 还可抑制MST1R、AXL、ROS1、MKNK1/2、FLT3、MERTK、DDR1和DDR2，其对应的IC50值分别为11 nM、2 nM、23 nM、7 nM、7 nM、10 nM、0.1 nM 和 7 nM。 |
||
| S6662 |
AST-487 (NVP-AST487)AST-487 (NVP-AST487)，一种N,N'-二苯基脲，是Flt3的竞争性抑制剂，ki值为0.12 μM。除FLT3以外，AST487还抑制RET,KDR,c-KIT 和 c-ABL 激酶，IC50值低于1 μM。 |
||
| S9275 |
IsoguanosineIsoguanosine (Crotonoside)抑制 FLT3 和 HDAC3/6 治疗AML。Isoguanosine 是巴豆（Croton tiglium）种子中天然存在的鸟苷的活性异构体。 |
||
| S8442 |
TAK-659TAK-659是一种有效的、选择性的SYK抑制剂。IC50为3.2 nM。对其他激酶具有选择性，对FLT3也能有效抑制，IC50为4.6 nM。 |
||
| S6839 |
MRX-2843MRX-2843 (UNC2371) 是酪氨酸激酶 MERTK 和 FLT3 的口服活性双重抑制剂，对应的IC50值分别为1.3 nM和0.64 nM。 |
||
| S8229 |
Brigatinib (AP26113)Brigatinib (AP26113) 是一种有效的、选择性的ALK抑制剂，IC50=0.6 nM；也是ROS1抑制剂，IC50=0.9 nM。它还能以相对较低的效力抑制IGF-1R、FLT3、FLT3(D835Y)和EGFR。 |
Immunoblotting analysis of H3122 and H3122-CER cells showing that brigatinib did not inhibit EGFR phosphorylation (p-EGFR). Total EGFR (t-EGFR) is also shown. Actin was used as a loading control. The cells were treated with brigatinib for 2 hours.
|
|
| S9662 |
UNC2025UNC2025 是一种有效的、口服活性的 FLT3 和 MER 的双重抑制剂，对应的IC50值分别为0.35 nM和0.46 nM。UNC2025 还抑制 AXL、TRKA、TRKC、QIK、TYRO3、SLK、NuaK1、Kit (c-Kit) 和 Met (c-Met)，对应的IC50值分别为1.65 nM、1.67 nM、4.38 nM、5.75 nM、5.83 nM、6.14 nM、7.97 nM、8.18 nM 和 364 nM。 |
||
| S7545 |
G-749G-749是一种新型有效的FLT3抑制剂，对FLT3(WT),FLT3(D835Y),和Mer的IC50分别为0.4 nM,0.6nM 和 1nM，对其它酪氨酸激酶效果较低。 |
||
| S6060 |
HPK1-IN-2HPK1-IN-2 是一种有效的和口服活性的 hematopoietic progenitor kinase-1 (HPK1, a serine/threonine Ste20-related protein kinase)、Lck 和 Flt3 的抑制剂，其IC50值分别为 <0.05 μM、<0.5 μM 和 <0.05 μM。HPK1-IN-2 具有抗肿瘤的活性。 |
||
| S1099 |
SKLB4771 (FLT3-IN-1)SKLB4771是一种有效、选择性的人类受体型酪氨酸蛋白激酶FLT3抑制剂，IC50为10 nM。 |
||
| S7754 |
Gilteritinib (ASP2215)Gilteritinib (ASP2215)是小分子FLT3/AXL抑制剂，对FLT3和AXL的IC50值为0.29 nM和0.73 nM。其抑制c-KIT的IC50值约为抑制FLT3的800倍。 |
||
| S7003 |
AZD2932AZD2932 是一种有效的多靶点蛋白酪氨酸激酶抑制剂，对VEGFR-2，PDGFRβ，Flt-3，和 c-Kit 的 IC50 分别为 8 nM，4 nM，7 nM，和 9 nM。 |
||
| S7818 |
Pexidartinib (PLX3397)Pexidartinib (PLX3397)是一种口服有效的多靶点CSF-1R，Kit (c-Kit)，和 FLT3受体酪氨酸激酶抑制剂，其IC50分别为20 nM, 10 nM 和 160 nM。Pexidartinib (PLX3397) 可以诱导细胞凋亡和坏死，并具有抗肿瘤活性。Phase 3。 |
(a) Reduced tumour burden in PLX3397 (PLX) treated mice relative to untreated (NT) (n=6, P=.015; unpaired t-test). Bars represent total tumour volume with number of identified tumours indicated above each bar.
|
|
| S7119 |
Go6976Go6976 (PD406976)是一种强效的PKC抑制剂，其对PKC (老鼠大脑), PKCα, and PKCβ1的IC50分别为7.9nM，2.3 nM, 和 6.2 nM 。此外，也是JAK2 和 Flt3的强抑制剂。 |
Erk5 activation depends on Mek5, classical PKC and Mek1/2. MOVAS cells were serum-starved overnight and then treated for 1 h if not indicated otherwise with inhibitors targeting Jnk (SP600125, 10 μM), p38 (SB203580, 10 μM), Mek1/2 (CI-1040, 3 μM), Jak2 (AG490, 10 μM), Src (SU6656, 0.5 μM), Go6983 (PKC, 1 μM), Gö6976 (classical PKC, 1 μM), proteasomes (MG132, 25 μM), TPA (100 ng/ml for 15 min to activate PKCs or overnight to inhibit) and Mek5 (BIX02189, 1 μM), as well as Ca2 + chelators (EDTA, 2 mM; BAPTA-AM, 10 μM; both with 30 min preincubation), followed by stimulation with 20 ng/ml PDGF-BB for 10 min. Total cell lysates (TCL) were prepared and subjected to SDS-PAGE. Erk5 and PDGFRβ activities were measured by band shift and Tyr857 phosphorylation, respectively, using immunoblotting. Panel E and G show representative immunoblots. |
|
| S7533 |
AMG 925AMG 925是一种有效的，且口服具有生物活性的双重FLT3/CDK4抑制剂，IC50分别为1 nM 和 3 nM。 |
| 目录号 | 产品描述 | 文献引用 | 实验数据 |
|---|---|---|---|
| S1040 |
Sorafenib (BAY 43-9006) tosylateSorafenib (BAY 43-9006) tosylate是Raf-1和B-Raf的多重激酶抑制剂，无细胞试验中IC50分别为6 nM和22 nM。Sorafenib 还可抑制VEGFR-2、VEGFR-3、PDGFR-β、Flt-3和c-KIT，对应的IC50值分别为90 nM、20 nM、57 nM、59 nM和68 nM。Sorafenib Tosylate 可诱导autophagy、apoptosis并激活ferroptosis，并具有抗肿瘤活性。 |
Inhibition of breast cancer cell growth using sorafenib. MCF-7 breast cancer cells were treated with increasing concentrations of sorafenib for 5 days. Cell number was measured using a colorimetric growth assay (crystal violet stain) and expressed relative to DMSO treated control cells. |
|
| S1048 |
Tozasertib (VX-680, MK-0457)Tozasertib (VX-680, MK-0457)是一种pan-Aurora抑制剂，对Aurora A作用最强，无细胞试验中Kiapp为0.6 nM，而对Aurora B/Aurora C的作用较弱，对Aurora A选择性比其他55种激酶高100倍。唯二的例外是 Fms-related tyrosine kinase-3 (FLT-3) 和 BCR-ABL tyrosine kinase，也可被 Tozasertib 抑制，对应的Ki值均为30 nM和30 nM。Tozasertib 可诱导凋亡和自噬。Phase 2。 |
Senescence induction upon PKCι depletion combined with aurora kinase inhibition. ( a) MCF7 cells were transfected as above to deplete PKCι . Two days after transfection, cells were treated for the indicated time period with 400 n M VX-680. Medium with VX-680 was then removed and fresh medium was added. Cells were stained for SA-b -gal activity 5 days after the start of transfection.* indicates a P value <0.05. ( b) MCF7 cells were treated as above. Five days after transfection, cells were fixed and assessed for the presence of gH2AX foci by immunofluorescence microscopy. (c, d) MCF7 cells were treated with dimethyl sulfoxide (DMSO) control or 400 n M VX-680 for the indicated time periods. Total cell lysates were then analyzed by western blotting for levels of p21 and GAPDH (as loading control). A representative blot is shown in panel c. Quantitation of changes in p21 levels (normalized to vehicle-treated controls) is shown in panel d. The data shown are the means ±s.e. of three independent experiments. |
|
| S1460 |
SP600125SP600125 (Nsc75890)是一种广谱JNK抑制剂，作用于JNK1、JNK2和JNK3，无细胞试验中IC50分别为40 nM、40 nM和90 nM，比作用于MKK4选择性高10倍，比作用于MKK3、MKK6、PKB和PKCα选择性高25倍，比作用于ERK2、p38、Chk1、EGFR等选择性高100倍。SP600125也是一种广谱的serine/threonine kinases抑制剂，包括Aurora kinase A、FLT3和TRKA，对应的IC50值为60 nM、90 nM和70 nM。SP600125可抑制自噬而激活细胞凋亡。 |
Loss of DUSP4 function upregulates IL-6 and IL-8 and enhances mammosphere growth. Immunoblot analysis of MDA-231 cells after treatment of 24 hours with 1 umol/L selumetinib (MEKi) or 10 umol/L SP600125 (JNKi). I, MDA-231 mammosphere formation quantitated by GelCount software 7 days after siRNA transfection. Where indicated, selumetinib (MEKi) or SP600125 (JNK1) or the combination was added to the mammosphere cultures.
|
|
| S1111 |
Foretinib (GSK1363089)Foretinib (GSK1363089, EXEL-2880, XL-880, GSK089) 是一种ATP竞争性的HGFR和VEGFR抑制剂，对Met (c-Met)和KDR作用最强，在无细胞试验中IC50分别为0.4 nM和0.9 nM。对Ron， Flt-1/3/4， Kit (c-Kit)， PDGFRα/β和Tie-2作用效果稍弱，对FGFR1和EGFR几乎没有抑制活性。Phase 2。 |
c-MET/RON inhibitors restore sensitivity to lapatinib in SK-BR-3-LR cells. Cell growth was determined using the sulforhodamine B assay. The concentration used was 0.1 uM for crizotinib, MGCD-265, XL880, sunitinib, dasatinib, and TAE-684I. The phosphorylation of HER2, AKT and ERK1/2 was determined by Western blotting.
|
|
| S2194 |
R406R406 是一种有效的 Syk 抑制剂，无细胞试验中IC50为41 nM，对Syk抑制作用强，但是不抑制Lyn，对Flt3的作用比对Syk低5倍。R406 可诱导凋亡。Phase 1。 |
Platelets (3 x 108/mL) were preincubated with Y27632 (10 uM), R406 (1 uM), or a combination of Y27632 and R406 for 20 minutes followed by stimulation with oxLDL (50 ug/mL) for 15 seconds and lysis. Samples were then separated by SDS-PAGE and were immunoblotted for phospho-MLCSer19, followed by reprobing for β-tubulin. (Fi) Representative blots. (Fii) Densitometric analysis of 3 independent experiments. *P < .05. Data are presented as mean ± SEM. Experiments were carried out in the presence of apyrase (2 U/mL), indomethacin (10 uM), and EGTA (1 mM).
|
|
| E0933New |
AristolactamAristolactam (Aristolactam I) is the main active ingredient in the Aristolochia plant species, which have been associated with severe nephrotoxicity. |
||
| S7002New |
ZotiraciclibZotiraciclib (SB1317; TG02)是一种新型小分子CDK/JAK2/FLT3抑制剂，对CDK1、2和9的IC50分别为9、5和3 nM，抑制FLT3的IC50为19 nM，抑制JAK2的IC50为19 nM。 |
||
| S9892New |
HM43239HM43239 是一种新型强效小分子 FLT3 抑制剂，不仅选择性抑制 FLT3 野生型、ITD 突变体或 TKD 突变，还选择性抑制 FLT3 ITD/TKD 双突变。 HM43239 对 FLT3 WT、FLT3 ITD 和 FLT3 D835Y 激酶的 IC50 分别为 1.1 nM、1.8 nM 和 1.0 nM。 |
||
| S9779New |
Emavusertib (CA-4948)Emavusertib (CA-4948) 是一种有效的、口服生物可利用的 interleukin-1 receptor-associated kinase 4/FMS-like Tyrosine Kinase 3 (IRAK4/FLT3) 的抑制剂，具有抗肿瘤活性。 |
||
| S1526 |
Quizartinib (AC220)Quizartinib (AC220)是一种二代FLT3抑制剂，作用于Flt3(ITD/WT)，在MV4-11和 RS4;11细胞中IC50分别为1.1 nM/4.2 nM，作用于Flt3比作用于KIT，PDGFRA，PDGFRB，RET，和CSF-1R选择性高10倍。Quizartinib (AC220)可诱导肿瘤细胞的凋亡。Phase 3。 |
Cotreatment with JQ1 and AC220 synergistically induces apoptosis of FLT3-ITD–expressing AML cells. MV4-11 cells were treated with the indicated concentrations of AC220 and/or JQ1 for 24 hours. At the end of treatment, immunoblot analyses were conducted as indicated. The numbers beneath the blots represent densitometry analysis conducted on representative blots.
|
|
| S1018 |
Dovitinib (TKI-258)Dovitinib (TKI-258, CHIR-258)是一种多靶点的RTK抑制剂，在无细胞试验中对III型(FLT3/c-Kit)作用最强，IC50为1 nM/2 nM，同时也作用于IV类(FGFR1/3)和V类(VEGFR1-4) RTKs，IC50为8-13 nM，但对InsR，EGFR，c-Met，EphA2，Tie2，IGF-1R和HER2作用较弱。Phase 4。 |
Orthotopic xenografts of HNSCC cell lines (A) SCC-1 and (B) OSC-19 were treated with dovitinib (20 mg/kg/day). In addition, the OSC-19 xenografts were treated with +/ radiation therapy. Marker, mean for triplicate; bars, SE. Statistical significance by unpaired t-test, p < 0.05. |
|
| S2736 |
Fedratinib (TG101348)Fedratinib (SAR302503, TG101348)是一种选择性JAK2抑制剂，在无细胞试验中IC50为3 nM，作用于JAK2比作用于JAK1和JAK3选择性高35和334倍。Fedratinib也可抑制 FMS-like tyrosine kinase 3 (FLT3) 和 Ret (c-RET)，对应的IC50值分别为15 nM和48 nM。Fedratinib有潜在的抗肿瘤活性。Fedratinib可抑制细胞增殖并促进凋亡。Phase 2。 |
Colony-forming assay results showing that the Jak2 inhibitor TG101348 reduces CFU-GM colonies generated from mutant fetal liver R2 cells. Results from 4 independent control or mutant fetal livers treated with TG101348 or dimethylsulfoxide (DMSO) are shown (mean ?SD). ***P < .001.
|
|
| S1003 |
Linifanib (ABT-869)Linifanib (ABT-869, AL39324, RG3635)是一种新型有效的ATP竞争性VEGFR/PDGFR抑制剂，作用于KDR，CSF-1R，Flt-1/3和PDGFRβ，其IC50分别为4 nM，3 nM，3 nM/4 nM和66 nM，对突变激酶依赖性癌细胞（即FLT3）最有效。Linifanib (ABT-869) 可诱导自噬和凋亡。Phase 3。 |
(B and C) KMCH-1 cells were plated alone (monoculture) or together with PDGF-BB-secreting LX-2 cells (co-culture) in a transwell insert co-culture system (KMCH-1 cells in the bottom wells and LX-2 cells in the inserts; 1:1 ratio) for 2 days. Cells were treated as indicated with vehicle, rhTRAIL (10 ng/ml for 6 h on day 2), rhTRAIL plus imatinib [rhTRAIL:10 ng/ml for 6 h on day 2; Imatinib: 5 μmol/L for 24 h (day2)], or rhTRAIL plus linifanib [rhTRAIL: 10 ng/ml for 6 h on day 2; Linifanib:0.5 μmol/L for 24 h (day2)]. After rhTRAIL treatment for 6 h,KMCH-1 cells were analysed for apoptotic nuclear morphology by DAPI-staining (B) and for DNA fragmentation by transferasemediated dUTP nick end labelling assay (C) with quantification of apoptotic nuclei by fluorescence microscopy. |
|
| S2730 |
Crenolanib (CP-868596)Crenolanib (CP-868596, ARO 002)是一种有效的，选择性PDGFRα/β抑制剂，在CHO细胞中Kd为2.1 nM/3.2 nM，也能有效抑制FLT3，对D842V突变型敏感对V561D突变型不敏感，作用于PDGFR比作用于c-Kit，VEGFR-2，TIE-2，FGFR-2，EGFR，erbB2，和Src的选择性高100倍以上。Crenolanib可辅助诱导线粒体自噬。 |
Western blot analysis using 4G10 and anti-FLT3 antibody after immunoprecipitation with anti-FLT3 antibody and Western blot analysis of phospho-ERK (pERK) and ERK performed on whole cell lysates from HB119 and Molm14 cells. Cells were exposed to 100 nM crenolanib for 60 min.
|
|
| S2198 |
SGI-1776 free baseSGI-1776 free base是一种新型的，ATP竞争性Pim1抑制剂，无细胞试验中IC50为7 nM，比作用于Pim2和Pim3选择性分别高50和10倍，也有效作用于Flt3和haspin。SGI-1776 可诱导凋亡和自噬。Phase 1。 |
VCaP cells were steroid starved overnight then treated with 10nM R1881 and PIM kinase inhibitor SGI-1776 as indicated for 4 hours. Total protein lysates were analyzed by Western blot with antibodies against P-AR S213, AR (total), P-4EBP1 Thr 37/46, and tubulin.
|
|
| S1533 |
R406 (free base)R406 (free base) 是一种有效的Syk抑制剂，无细胞试验中IC50为41 nM，强效抑制Syk而不能抑制Lyn，对Flt3作用效果低5倍。R406 (free base) 可触发凋亡。Phase 1。 |
(C) Z-138 and JEKO-1 cells were simultaneously exposed to sorafenib and R406 at the indicated doses, and cell viability was determined at 48 hours by annexin V/PI staining. Bars represent the mean ± SD of 3 independent experiments. CI value is indicated for each combination. (D) Primary MCL cells from 7 patients were simultaneously exposed to sorafenib and R406 at the indicated doses for 48 hours, and cell viability was determined as above. Bars represent the mean ± SEM of all the samples analyzed. CI value is indicated for each combination. |
|
| S1244 |
Amuvatinib (MP-470)Amuvatinib (MP-470, HPK 56) 是一种有效的，作用于c-Kit、PDGFα和Flt3的多靶点抑制剂，IC50分别为10 nM、40 nM和81 nM。Amuvatinib 可抑制c-MET和c-RET。Amuvatinib 还具有DNA修复蛋白Rad51抑制剂及抗肿瘤的活性。Phase 2。 |
Inactivation of AXL by MP470 reverses epithelial to mesenchymal transition. Immunoblot analyses of lysates from TGFβ/TNFα- treated MCF10A cells treated with varying amounts of MP470 for 72 hours.
|
|
| S1043 |
Tandutinib (MLN518)Tandutinib (MLN518, CT53518, NSC726292)是一种有效的FLT3拮抗剂，IC50为0.22 μM，同时也抑制PDGFR和c-Kit，对FLT3作用效果比CSF-1R强15到20倍，比FGFR， EGFR和KDR等强100倍以上。Phase 2。 |
|
|
| S2692 |
TG101209TG101209是一种选择性的JAK2抑制剂，无细胞试验中IC50为6 nM，对Flt3和RET (c-RET)作用效果稍弱，IC50分别为25 nM和17 nM，作用于JAK2比作用于JAK3选择性高30倍左右，对JAK2V617F和MPLW515L/K突变型敏感。 |
EGFR-ERCC1 effect on survival. QGP1 cells were transfected with Scrambled, ERCC1, EGFR, or EGFR-ERCC1 siRNA. Following 48 hours of siRNA transfection, Scrambled siRNA and ERCC1 siRNA-transfected cells were treated with 1 umol/L gefitinib or 125 nmol/L NU7026 (DNAPK inhibitor), or both, while EGFR siRNA and EGFR-ERCC1 siRNA-transfected cells were treated with 125 nmol/L of NU7026 1 hour prior 4 Gy IR treatment. Survival of these cells was then assessed 72 hours following IR treatment via MTT assay. The graphs show percentage of survival from 3 independent experiments as compared with untreated control. Bars show SD. Asterisks show statistical significance (*,P < 0.05; **, P < 0.01; ***, P < 0.001; NS, nonsignificant).
|
|
| S2158 |
KW-2449KW-2449是一种多靶点抑制剂，最有效作用于Flt3，IC50为6.6 nM，作用于Flt3， Bcr-Abl和Aurora A适度有效；对PDGFRβ， IGF-1R， EGFR没有抑制效果。Phase 1。 |
Western blot analysis of p-histone and histone. 0-10μM KW2449 was added.
|
|
| S1181 |
ENMD-2076ENMD-2076 选择性地作用于 Aurora A 和 Flt3，IC50分别为14 nM和1.86 nM，作用于Aurora A比作用于Aurora B选择性高25倍，对RET、SRC、NTRK1/TRKA、CSF1R/FMS、VEGFR2/KDR、FGFR和PDGFRα作用效果稍弱。ENMD-2076 可抑制各种人类实体瘤和造血癌细胞系的生长，其IC50值为0.025至0.7μM，可诱导凋亡和G2/M期停滞。Phase 2。 |
Breast cancer cells line MDA-MB-231 were treated with the indicated concentrations of ENMD-2076.
|
|
| S7083 |
Ceritinib (LDK378)Ceritinib (LDK378)是一种有效的ALK抑制剂，在无细胞试验中IC50为0.2 nM。Ceritinib (LDK378)还可抑制IGF-1R、InsR、STK22D和FLT3对应的IC50值分别为8 nM、7 nM、23 nM和60 nM。Phase 3。 |
Quantitation of crystal violet uptake by ORF-expressing cells exposed to crizotinib (CRZ) or ceritinib (CER) normalized to Lac Z. Mean and SE are shown for six (CRZ) or four (CER) independent experiments of three replicates each.
|
|
| S8032 |
PRT062607 (P505-15) HClPRT062607 (P505-15, BIIB057, PRT-2607)是一种新型的，高度选择性Syk抑制剂，无细胞试验中IC50为1 nM，作用于Syk比作用于Fgr，PAK5，Lyn，FAK，Pyk2, FLT3, MLK1 和Zap70选择性高80倍以上。 |
Dectin-1 is involved in activation of NLRP3-inflammasome by Malassezia spp. IL-1b secretion from mature human mono-DCs incubated with Syk-inhibitors (piceatannol, R406 or P505), 1 h prior to exposure to medium, MSU, b-glucan, nigericin or live M. furfur (MOI = 10) was determined after 6 h by ELISA.
|
|
| S7397 |
Sorafenib (BAY 43-9006)Sorafenib (BAY 43-9006, NSC-724772)是Raf-1和B-Raf的多重激酶抑制剂，无细胞试验中IC50分别为6 nM和22 nM。Sorafenib 还可抑制VEGFR-2、VEGFR-3、PDGFR-β、Flt-3和c-KIT，对应的IC50值分别为90 nM、20 nM、57 nM、59 nM和68 nM。Sorafenib 可诱导autophagy、apoptosis并激活ferroptosis，Sorafenib 具有抗肿瘤活性。 |
Involvement of EV linc-VLDLR in tumor cell responses to chemotherapy. Cells were incubated with sorafenib, camptothecin, or doxorubicin. EVs were obtained after 24 hours, and qRT-PCR was performed for linc-VLDLR. The bars represent the mean ?SEM of the increase in cell viability from 3 independent studies. *, P < 0.05.
|
|
| S8057 |
Pacritinib (SB1518)Pacritinib (SB1518)是有效的选择性Janus Kinase 2 (JAK2)和Fms-Like Tyrosine Kinase-3 (FLT3)抑制剂，无细胞试验中IC50分别为23和22 nM。Phase 3。 |
Phosphorylation of the CSF-1R targets indicated was examined by immunoblotting
|
|
| S4001 |
Cabozantinib malate (XL184)Cabozantinib malate (XL184)是Cabozantinib的苹果酸盐，是有效的VEGFR2抑制剂，IC50为0.035 nM，也抑制c-Met， RET (c-RET)， Kit (c-Kit)， Flt-1/3/4， Tie2和AXL，无细胞试验中IC50分别为1.3 nM， 4 nM， 4.6 nM， 12 nM/11.3 nM/6 nM， 14.3 nM和7 nM。Cabozantinib malate (XL184)可诱导细胞凋亡。 |
Effects of AXL inhibitors on induction of pAKT and rescue of pERK following AXL overexpression. R428, 500 nmol/L; XL184, 3 umol/L; XL880, 100 nmol/L; in the presence or absence of 2 umol/L PLX4720. shAXL is a positive control.
|
|
| S8023 |
TCS 359TCS 359是一种有效的FLT3抑制剂，IC50为42 nM。 |
||
| S2018 |
ENMD-2076 L-(+)-Tartaric acidENMD-2076 L-(+)-Tartaric acid 是ENMD-2076的酒石酸，选择性作用于Aurora A和VEGFR(Flt3)，IC50分别为14 nM和1.86 nM，作用于Aurora A比作用于Aurora B选择性高25倍，对VEGFR2/KDR和VEGFR3， FGFR1和FGFR2和PDGFRα作用效果稍弱。Phase 2。 |
Breast cancer cells line MDA-MB-231 were treated with the indicated concentrations of ENMD-2076.
|
|
| S7765 |
Dovitinib (TKI258) LactateDovitinib (TKI258, CHIR258) Lactate是Dovitinib的乳酸盐，Dovitinib是一种多靶点的PTK抑制剂，主要对第III类(FLT3/c-Kit)发挥作用，IC50为1 nM/2 nM，对第IV 类(FGFR1/3)和第V 类(VEGFR1-4) RTKs也有效，IC50为8-13 nM，对InsR，EGFR，c-Met，EphA2，Tie2，IGFR1 和HER2作用较差。Phase 4。 |
(c) Percent survival for the AGS cancer cell line is shown with FGFR2 inhibitors of varying specificity. (d) The KatoIII diffuse gastric cancer cell line was treated with FGFR2 inhibitors of varying specificity. The Y-axis depicts percent survival versus the X-axis with log concentrations. In all panels, error bars represent standard error of the mean. The difference in percent cell survival between KatoIII and AGS cells was statistically significant (P <0.05) at the three highest concentrations of all drugs, except Brivanib which was only significant at the highest concentration. |
|
| S7576 |
UNC2025 HClUNC2025 HCl 是一种有效且口服生物可利用的双重MER/FLT3抑制剂，IC50分别为0.74 nM 和 0.8 nM，选择性比作用于Axl和 Tyro3大约高20倍。 |
||
| S0278 |
SU5614SU5614 (Chloro-SU5416, Chloro-Semaxanib) 是一种小分子 receptor tyrosine kinases (RTK) 的抑制剂，对 VEGFR-2、c-kit 以及野生型和突变型 FLT3 均有抑制作用。SU5614 可减少细胞增殖并诱导凋亡。 |
||
| S8899 |
FF-10101FF-10101是一种新型的不可逆的FLT3抑制剂，对FLT3(WT)和 FLT3(D835Y)的ic50分别为0.20 nM 和 0.16 nM。 |
||
| S7014 |
Merestinib (LY2801653)Merestinib (LY2801653) 是一种2型ATP竞争型的慢抑制剂，抑制Met (c-Met)酪氨酸激酶，Ki值为2 nM。药效的停留时间为0.00132 min(-1)，t1/2为525 min。Merestinib (LY2801653) 还可抑制MST1R、AXL、ROS1、MKNK1/2、FLT3、MERTK、DDR1和DDR2，其对应的IC50值分别为11 nM、2 nM、23 nM、7 nM、7 nM、10 nM、0.1 nM 和 7 nM。 |
||
| S6662 |
AST-487 (NVP-AST487)AST-487 (NVP-AST487)，一种N,N'-二苯基脲，是Flt3的竞争性抑制剂，ki值为0.12 μM。除FLT3以外，AST487还抑制RET,KDR,c-KIT 和 c-ABL 激酶，IC50值低于1 μM。 |
||
| S9275 |
IsoguanosineIsoguanosine (Crotonoside)抑制 FLT3 和 HDAC3/6 治疗AML。Isoguanosine 是巴豆（Croton tiglium）种子中天然存在的鸟苷的活性异构体。 |
||
| S8442 |
TAK-659TAK-659是一种有效的、选择性的SYK抑制剂。IC50为3.2 nM。对其他激酶具有选择性，对FLT3也能有效抑制，IC50为4.6 nM。 |
||
| S6839 |
MRX-2843MRX-2843 (UNC2371) 是酪氨酸激酶 MERTK 和 FLT3 的口服活性双重抑制剂，对应的IC50值分别为1.3 nM和0.64 nM。 |
||
| S8229 |
Brigatinib (AP26113)Brigatinib (AP26113) 是一种有效的、选择性的ALK抑制剂，IC50=0.6 nM；也是ROS1抑制剂，IC50=0.9 nM。它还能以相对较低的效力抑制IGF-1R、FLT3、FLT3(D835Y)和EGFR。 |
Immunoblotting analysis of H3122 and H3122-CER cells showing that brigatinib did not inhibit EGFR phosphorylation (p-EGFR). Total EGFR (t-EGFR) is also shown. Actin was used as a loading control. The cells were treated with brigatinib for 2 hours.
|
|
| S9662 |
UNC2025UNC2025 是一种有效的、口服活性的 FLT3 和 MER 的双重抑制剂，对应的IC50值分别为0.35 nM和0.46 nM。UNC2025 还抑制 AXL、TRKA、TRKC、QIK、TYRO3、SLK、NuaK1、Kit (c-Kit) 和 Met (c-Met)，对应的IC50值分别为1.65 nM、1.67 nM、4.38 nM、5.75 nM、5.83 nM、6.14 nM、7.97 nM、8.18 nM 和 364 nM。 |
||
| S7545 |
G-749G-749是一种新型有效的FLT3抑制剂，对FLT3(WT),FLT3(D835Y),和Mer的IC50分别为0.4 nM,0.6nM 和 1nM，对其它酪氨酸激酶效果较低。 |
||
| S6060 |
HPK1-IN-2HPK1-IN-2 是一种有效的和口服活性的 hematopoietic progenitor kinase-1 (HPK1, a serine/threonine Ste20-related protein kinase)、Lck 和 Flt3 的抑制剂，其IC50值分别为 <0.05 μM、<0.5 μM 和 <0.05 μM。HPK1-IN-2 具有抗肿瘤的活性。 |
||
| S1099 |
SKLB4771 (FLT3-IN-1)SKLB4771是一种有效、选择性的人类受体型酪氨酸蛋白激酶FLT3抑制剂，IC50为10 nM。 |
||
| S7754 |
Gilteritinib (ASP2215)Gilteritinib (ASP2215)是小分子FLT3/AXL抑制剂，对FLT3和AXL的IC50值为0.29 nM和0.73 nM。其抑制c-KIT的IC50值约为抑制FLT3的800倍。 |
||
| S7003 |
AZD2932AZD2932 是一种有效的多靶点蛋白酪氨酸激酶抑制剂，对VEGFR-2，PDGFRβ，Flt-3，和 c-Kit 的 IC50 分别为 8 nM，4 nM，7 nM，和 9 nM。 |
||
| S7818 |
Pexidartinib (PLX3397)Pexidartinib (PLX3397)是一种口服有效的多靶点CSF-1R，Kit (c-Kit)，和 FLT3受体酪氨酸激酶抑制剂，其IC50分别为20 nM, 10 nM 和 160 nM。Pexidartinib (PLX3397) 可以诱导细胞凋亡和坏死，并具有抗肿瘤活性。Phase 3。 |
(a) Reduced tumour burden in PLX3397 (PLX) treated mice relative to untreated (NT) (n=6, P=.015; unpaired t-test). Bars represent total tumour volume with number of identified tumours indicated above each bar.
|
|
| S7119 |
Go6976Go6976 (PD406976)是一种强效的PKC抑制剂，其对PKC (老鼠大脑), PKCα, and PKCβ1的IC50分别为7.9nM，2.3 nM, 和 6.2 nM 。此外，也是JAK2 和 Flt3的强抑制剂。 |
Erk5 activation depends on Mek5, classical PKC and Mek1/2. MOVAS cells were serum-starved overnight and then treated for 1 h if not indicated otherwise with inhibitors targeting Jnk (SP600125, 10 μM), p38 (SB203580, 10 μM), Mek1/2 (CI-1040, 3 μM), Jak2 (AG490, 10 μM), Src (SU6656, 0.5 μM), Go6983 (PKC, 1 μM), Gö6976 (classical PKC, 1 μM), proteasomes (MG132, 25 μM), TPA (100 ng/ml for 15 min to activate PKCs or overnight to inhibit) and Mek5 (BIX02189, 1 μM), as well as Ca2 + chelators (EDTA, 2 mM; BAPTA-AM, 10 μM; both with 30 min preincubation), followed by stimulation with 20 ng/ml PDGF-BB for 10 min. Total cell lysates (TCL) were prepared and subjected to SDS-PAGE. Erk5 and PDGFRβ activities were measured by band shift and Tyr857 phosphorylation, respectively, using immunoblotting. Panel E and G show representative immunoblots. |
|
| S7533 |
AMG 925AMG 925是一种有效的，且口服具有生物活性的双重FLT3/CDK4抑制剂，IC50分别为1 nM 和 3 nM。 |
沪公网安备 31011502012800号